What is BD?
BD is widely perceived as a global medical technology company that develops and manufactures medical devices, diagnostic systems, laboratory equipment, and healthcare solutions. The company supports hospitals, laboratories, and healthcare providers through innovations in patient safety, drug delivery, diagnostics, and biosciences. Its comprehensive portfolio addresses critical needs across various healthcare segments, from point-of-care diagnostics to advanced drug delivery systems, positioning BD as a key player in enhancing patient outcomes and operational efficiency within the healthcare ecosystem.
How much funding has BD raised?
BD has raised a total of $71M across 3 funding rounds:
Stock Offering
$12M
Grant
$24M
Other Financing Round
$35M
Stock Issuance/Offering (1962): $12M, investors not publicly disclosed
Grant (2020): $24M led by U.S. Department of Health and Human Services and U.S. Department of Defense
Other Financing Round (2025): $35M, investors not publicly disclosed
Key Investors in BD
U.S. Department of Health and Human Services
The U.S. Department of Health and Human Services is a cabinet-level department of the U.S. federal government dedicated to protecting the health of all Americans and providing essential human services, especially for those least able to help themselves. It oversees numerous agencies, including the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), playing a crucial role in public health policy, research, and regulation.
U.S. Department of Defense
The U.S. Department of Defense is responsible for coordinating and supervising all agencies and functions of the government directly related to national security and the United States Armed Forces. It plays a role in advancing defense technologies and ensuring the health and readiness of military personnel, which can involve investments in medical technologies relevant to defense and veteran care.
What's next for BD?
The recent major strategic investment signifies BD's ongoing commitment to innovation and expansion within the dynamic medical technology landscape. With a history of securing substantial capital, including a notable grant in 2020, BD is well-positioned to leverage this latest financing for research and development, market penetration, and potential strategic acquisitions. The company's focus on diagnostics, biosciences, and healthcare solutions suggests a forward-looking strategy aimed at addressing evolving global health challenges and enhancing healthcare delivery through technological advancements.
See full BD company page
